Published in
American Association for the Advancement of Science, Science Translational Medicine, 442(10), 2018
DOI: 10.1126/scitranslmed.aah4807
Links
Tools
A rationally designed NRP1-independent superagonist SEMA3A mutant is an effective anticancer agent
Journal article published in 2018 by
Noemi Gioelli 
,
Federica Maione ,
Chiara Camillo ,
Michela Ghitti ,
Donatella Valdembri ,
Noemi Morello ,
Marie Darche,
Lorena Zentilin,
Gabriella Cagnoni,
Yaqi Qiu,
Mauro Giacca ,
Maurizio Giustetto ,
Michel Paques,
Ilaria Cascone,
Giovanna Musco
and other authors.
,
Federica Maione ,
Chiara Camillo ,
Michela Ghitti ,
Donatella Valdembri ,
Noemi Morello ,
Marie Darche,
Lorena Zentilin,
Gabriella Cagnoni,
Yaqi Qiu,
Mauro Giacca ,
Maurizio Giustetto ,
Michel Paques,
Ilaria Cascone,
Giovanna Musco
and other authors.
This paper was not found in any repository, but could be made available legally by the author.
Full text: Unavailable
Published version:
archiving forbidden
Data provided by 
Abstract
An NRP1-independent, non-natural SEMA3A mutant isoform is a parenterally deliverable anticancer drug that normalizes the vasculature.